Substance / Medication

Solifenacin

Overview

Active Ingredient
solifenacin
RxNorm CUI
322167

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Comparative efficacy of solifenacin and tamsulosin in alleviating stent-related symptoms: A systematic review and meta-analysis.
Harahap Dianita H, Adhyatma Kharisma P, Elbert Elbert et al. · Narra J · 2025
PMID: 40951488Meta-AnalysisFull text (PMC)
Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review.
Raman Gayathri, Tunnicliffe David, Lai Elise et al. · J Pediatr Urol · 2023
PMID: 36336627Meta-Analysis
Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
Wang Jipeng, Zhou Zhongbao, Cui Yuanshan et al. · Neurourol Urodyn · 2019
PMID: 30350884Meta-Analysis
Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?
Cardozo Linda, Herschorn Sender, Snijder Robert et al. · Int Urogynecol J · 2017
PMID: 27605255Meta-Analysis
Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.
Gong Mancheng, Dong Wenjing, Huang Guiying et al. · Curr Med Res Opin · 2015
PMID: 26211817Meta-Analysis
Solifenacin for overactive bladder: a systematic review and meta-analysis.
Luo Deyi, Liu Liangren, Han Ping et al. · Int Urogynecol J · 2012
PMID: 22310924Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Solifenacin (substance)
SNOMED CT
407030007
UMLS CUI
C1099677
RxNorm CUI
322167

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.